1. Home
  2. ERAS vs BSRR Comparison

ERAS vs BSRR Comparison

Compare ERAS & BSRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • BSRR
  • Stock Information
  • Founded
  • ERAS 2018
  • BSRR 1977
  • Country
  • ERAS United States
  • BSRR United States
  • Employees
  • ERAS N/A
  • BSRR N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • BSRR Major Banks
  • Sector
  • ERAS Health Care
  • BSRR Finance
  • Exchange
  • ERAS Nasdaq
  • BSRR Nasdaq
  • Market Cap
  • ERAS 439.7M
  • BSRR 411.5M
  • IPO Year
  • ERAS 2021
  • BSRR 1994
  • Fundamental
  • Price
  • ERAS $2.32
  • BSRR $28.95
  • Analyst Decision
  • ERAS Buy
  • BSRR Buy
  • Analyst Count
  • ERAS 6
  • BSRR 2
  • Target Price
  • ERAS $3.83
  • BSRR $33.50
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • BSRR 25.7K
  • Earning Date
  • ERAS 11-11-2025
  • BSRR 10-20-2025
  • Dividend Yield
  • ERAS N/A
  • BSRR 3.47%
  • EPS Growth
  • ERAS N/A
  • BSRR 18.55
  • EPS
  • ERAS N/A
  • BSRR 2.90
  • Revenue
  • ERAS N/A
  • BSRR $145,369,000.00
  • Revenue This Year
  • ERAS N/A
  • BSRR $8.30
  • Revenue Next Year
  • ERAS N/A
  • BSRR $3.74
  • P/E Ratio
  • ERAS N/A
  • BSRR $9.94
  • Revenue Growth
  • ERAS N/A
  • BSRR 2.12
  • 52 Week Low
  • ERAS $1.01
  • BSRR $22.42
  • 52 Week High
  • ERAS $3.31
  • BSRR $35.13
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 68.53
  • BSRR 42.12
  • Support Level
  • ERAS $1.78
  • BSRR $27.67
  • Resistance Level
  • ERAS $2.65
  • BSRR $30.44
  • Average True Range (ATR)
  • ERAS 0.20
  • BSRR 0.78
  • MACD
  • ERAS 0.05
  • BSRR -0.13
  • Stochastic Oscillator
  • ERAS 68.34
  • BSRR 34.69

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About BSRR Sierra Bancorp

Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.

Share on Social Networks: